MedTrace Logo

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2025-08-28

No results posted yet for this study

Summary

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Early Highly Effective Therapies Group

Highly Effective MS Therapy group of medications

DRUG

Escalation Therapies Group

Escalation MS Therapy group of medications

Sponsors & Collaborators

  • University of Nottingham

    collaborator OTHER

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Daniel Ontaneda, MD, MSc · The Cleveland Clinic

  • Nikos Evangelou, MD, DPhil · University of Nottingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2027-07-30
Completion
2027-07-30
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03535298 on ClinicalTrials.gov